Results 41 to 50 of about 2,196 (157)

High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides

Circulation Journal, 2015
Numerous randomized clinical trials have established statins as the major standard therapy for atherosclerotic diseases because these molecules decrease the plasma level of low-density lipoprotein (LDL) cholesterol and moderately increase that of plasma high-density lipoprotein (HDL) cholesterol.
Y. Uehara, G. Chiesa, K. Saku
openaire   +5 more sources

The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease? [PDF]

PLoS ONE, 2015
Cardiovascular disease (CVD) is the leading cause of death worldwide and new approaches for both diagnosis and treatment are required. Autoantibodies directed against apolipoprotein A-I (ApoA-I) represent promising biomarkers for use in risk ...
Sabrina Pagano, Hubert Gaertner, Fabrice Cerini, Tiphaine Mannic, Nathalie Satta, Priscila Camillo Teixeira, Paul Cutler, François Mach, Nicolas Vuilleumier, Oliver Hartley   +9 more
doaj   +1 more source

Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review

Journal of Lipid Research, 2014
Reduced levels of HDL cholesterol (HDL-C) are a strong independent predictor of coronary artery disease (CAD) risk. The major anti-atherogenic function of HDL is to mediate reverse cholesterol transport.
C. Roger White, David W. Garber, G.M. Anantharamaiah   +2 more
doaj   +1 more source

Beyond PEG: Emerging Polymer Lipid Alternatives for Lipid Nanoparticle (LNP) Formulations

Advanced Science, EarlyView.
This review discusses recent advances in PEG‐alternative LNP designs, including non‐PEG polymers, zwitterionic lipids, and polypeptides. It evaluates how surface‐engineering chemistry influences LNP formation and biological behavior, and highlights current limitations and opportunities of PEG‐alternative LNPs.
Zihnil A. I. Mazrad, Yi Ju, Stephen J. Kent, Colin W. Pouton, Kristian Kempe   +4 more
wiley   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source

Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1

Journal of Lipid Research, 2006
ABCA1 mediates the transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Apolipoprotein A-I (apoA-I) interactions with ABCA1-expressing cells elicit several responses, including removing cellular lipids, stabilizing ABCA1 protein ...
Chongren Tang, Ashley M. Vaughan, G.M. Anantharamaiah, John F. Oram   +3 more
doaj   +1 more source

An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. [PDF]

PLoS ONE, 2013
Apolipoprotein A-I (apoA-I) mimetic peptides are considered a promising novel therapeutic approach to prevent and/or treat atherosclerosis. An apoA-I mimetic peptide ELK-2A2K2E was designed with a reductionist approach and has shown exceptional activity ...
Michael Ditiatkovski, Wilissa D'Souza, Rajitha Kesani, Jaye Chin-Dusting, Judy B de Haan, Alan Remaley, Dmitri Sviridov   +6 more
doaj   +1 more source

Bile acid metabolism and signaling in human and animal health: A One Health perspective

iMetaOmics, EarlyView.
Bile acids maintain host homeostasis through enterohepatic circulation, microbial transformation, and bile acid receptor signaling, thereby regulating glucose and lipid metabolism, intestinal barrier integrity, and immunity. These effects support human disease intervention and health‐oriented animal production, reducing drug dependence and residue ...
Lei Li, Shuai Liu, Zhijun Cao, Yangchun Cao, Shengru Wu, Lu Deng, Junhu Yao, Jun Zhang   +7 more
wiley   +1 more source

Preservation of biological function despite oxidative modification of the apolipoprotein A-I mimetic peptide 4F [PDF]

Journal of Lipid Research, 2012
Myeloperoxidase (MPO)-derived hypochlorous acid induces changes in HDL function via redox modifications at the level of apolipoprotein A-I (apoA-I). As 4F and apoA-I share structural and functional properties, we tested the hypothesis that 4F acts as a reactive substrate for hypochlorous acid (HOCl).
C. Roger White, Geeta Datta, Amanda K.W. Buck, Manjula Chaddha, Gautam Reddy, Landon Wilson, Mayakonda N. Palgunachari, Mohammad Abbasi, G.M. Anantharamaiah   +8 more
openaire   +3 more sources

An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide

Journal of Lipid Research, 2009
Modifying apolipoprotein (apo) A-I mimetic peptides to include a proline-punctuated α-helical repeat increases their anti-inflammatory properties as well as allows better mimicry of full-length apoA-I function. This study compares the following mimetics,
Geoffrey D. Wool, Tomas Vaisar, Catherine A. Reardon, Godfrey S. Getz   +3 more
doaj   +1 more source